Navigation Links
Dehydrated tomatoes show promise for preventing prostate cancer
Date:5/28/2008

PHILADELPHIA New research suggests that the form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential, according to a report in the June 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

Processing of many edible plants through heating, grinding, mixing or drying dramatically increases their nutrition value, including their cancer prevention potential. It appears that the greatest protective effect from tomatoes comes by rehydrating tomato powder into tomato paste, said Valeri V. Mossine, Ph.D., research assistant professor of biochemistry at the University of Missouri.

The protective effect of tomato products against prostate cancer has been suggested in many studies, but researchers remain uncertain about the exact mechanisms. Mossine and colleagues demonstrated that FruHis, an organic carbohydrate present in dehydrated tomato products, exerts a strong protective effect.

Researchers divided rats into groups of 20 and fed them a control diet or a diet that included tomato paste, tomato powder or tomato paste plus additional FruHis. All animals were then injected with prostate cancer-causing chemicals.

Animals fed the tomato paste plus FruHis diet had the longest survival from cancer at 51 weeks compared with 50 weeks in the tomato powder group, 45 weeks in the tomato paste alone group and 40 weeks in the control group.

On post-mortem exam, prostate tumors were found in 10 percent of the rats that had been given a combination of tomato paste and FruHis, compared with 30 percent of animals in the tomato powder group, 25 percent in the tomato paste alone group and 60 percent in the control group.

Mossine said the protective effect of tomato-based products was restricted to prostate tumors, which is consistent with other research on tomatoes and cancer. Incidence of other tumors was too small to examine.

In vitro, Mossine and colleagues evaluated the anti-cancer properties of FruHis and 14 other D-fructose amino acids and found that FruHis in a concentrated form protected against DNA damage known to lead to prostate cancer. When combined with lycopene, FruHis stopped cancerous cell growth more than 98 percent of the time.

Before this study, researchers attributed the protective effect of tomatoes to ascorbic acid, carotenoids, or phenolic compounds, Mossine said. FruHis may represent a novel type of potential dietary antioxidant. Experiments like these suggest that a combination of FruHis and lycopene should be investigated as a potential therapeutic anti-tumor agent, not just a prevention strategy.

Although Mossine cautioned against drawing broad conclusions from this animal study, he said, the result may introduce an additional intrigue into an ongoing dispute over the beneficial effects of dietary lycopene and tomato products in lowering the risk of prostate cancer. Human trials are certainly warranted.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Fighting a Fungus That Thrives on Tomatoes
2. Two Drugs Show Promise Against Severe Constipation
3. New Antioxidant Drug Shows Promise Against Diabetes
4. Drug for Deadly Lung Disease Shows Promise
5. Unlocking the promise of clinical and translational science
6. UNC study firms up promise of potential new cervical cancer screening tool
7. Sorafenib Shows Promise for Heart-Lung Disease
8. New Surgical Technology Holds Promise of Painless, Scarless Procedures
9. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
10. Therapy Yields Promise for Fatal Neurological Condition
11. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... ... at creating a transparent, verifiable database to help the cannabis industry move towards ... Paragon hopes to deliver a faster technology with lower fees. Paragon will build ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has ... These illustrations show the diversity of the breastfeeding mothers, using bright colors ... of sizes. These illustrations are also available on tote bags, notepads, smartphone cases, ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! ... children to both their parents and God. “Congratulations! It's A Boy! God’s Gift: A ... a couple from Long Island, New York. , Published by Christian Faith Publishing, Dale ...
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: